Increasing nonalcoholic fatty liver disease-related mortality rates in the United States from 1999 to 2022.

Advanced Search

Fariha Ilyas, Hassam Ali, Pratik Patel, Shiza Sarfraz, Debargha Basuli, Alexa Giammarino, Sanjaya Kumar Satapathy

Author Information

Fariha Ilyas: Department of Internal Medicine, ECU health medical center/Brody School of Medicine, Greenville, North Carolina, USA. ORCID
Hassam Ali: Department of Internal Medicine, ECU health medical center/Brody School of Medicine, Greenville, North Carolina, USA. ORCID
Pratik Patel: Department of Gastroenterology, Mather Hospital/Hofstra University Zucker School of Medicine, Port Jefferson, New York, USA. ORCID
Shiza Sarfraz: Department of Internal Medicine, Quaid-e-Azam Medical College, Punjab, Pakistan. ORCID
Debargha Basuli: Department of Internal Medicine, ECU health medical center/Brody School of Medicine, Greenville, North Carolina, USA. ORCID
Alexa Giammarino: Department of Internal Medicine, North Shore University Hospital/Zucker School of Medicine at Hofstra University, Manhasset, New York, USA. ORCID
Sanjaya Kumar Satapathy: Department of Hepatology, North Shore University Hospital/Zucker School of Medicine at Hofstra University, Manhasset, New York, USA. ORCID

PMID: 37395738 DOI: 10.1097/HC9.0000000000000207

BACKGROUND: We examined trends in NAFLD-related mortality in the United States from 1999 to 2022, focusing on sex, racial differences, and specific age groups.
METHODS: We analyzed age-adjusted mortality rates (AAMRs) for NAFLD-related deaths using the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database and assessed differences between sex and racial groups.
RESULTS: Between 1999 and 2022, NAFLD-related mortality rose from an age-adjusted mortality rate (AAMR) of 0.2 to 1.7 per 100,000, with an average annual percent change (AAPC) of 10.0% (p < 0.001). In all, 85.4% of the cases were reported after 2008. Females (0.2-2 per 100,000, AAPC: 11.7%, p < 0.001) saw a steeper increase than males (0.2-1.3 per 100,000, AAPC: 9.3%, p < 0.001). White individuals' AAMR rose from 0.2 to 1.9 per 100,000 (AAPC: 10.8%, p < 0.001). Asian or Pacific Islanders (AAPI) increased from 0.2 in 2013 to 0.5 in 2022 (AAPC: 12.13%, p = 0.002), and American Indians or Alaska Natives (AI/AN) from 1 in 2013 to 2.2 in 2022 (AAPC: 7.9%, p = 0.001). African Americans (AA) showed an insignificant change (0.3-0.5 per 100,000, AAPC: 0.7%, p = 0.498). Regarding age, individuals 45-64 saw AAMR rise from 0.3 to 1.2 per 100,000 (AAPC: 6.5%, p < 0.001), and those 65+ from 0.2 to 6 per 100,000 (AAPC: 16.5%, p < 0.001). No change was observed in the 25-44 age group (AAMR: 0.2 per 100,000, AAPC: 0.0%, p = 0.008).
CONCLUSION: We report increased NAFLD-related mortality among both sexes and certain racial groups. The mortality rate increased for older populations, emphasizing the need for targeted public health measures and evidence-based interventions.

Alvarez CS, Graubard BI, Thistle JE, Petrick JL, McGlynn KA. Attributable fractions of nonalcoholic fatty liver disease for mortality in the united states: results from the third national health and nutrition examination survey with 27 years of follow-up. Hepatology. 2020;72:430–440.
Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–530.e1; quiz e60.
Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315:2284–2291.
Parikh ND, Marrero WJ, Wang J, Steuer J, Tapper EB, Konerman M, et al. Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States. Hepatology. 2019;70:487–495.
Almomani A, Kumar P, Onwuzo S, Boustany A, Krishtopaytis E, Hitawala A, et al. Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: A population-based study and review of literature. J Gastroenterol Hepatol. 2023;38:269–273.
Paik JM, Henry L, De Avila L, Younossi E, Racila A, Younossi ZM. Mortality related to nonalcoholic fatty liver disease is increasing in the united states. Hepatol Commun. 2019;3:1459–1471.
Murphy SL, Xu J, Kochanek KD, Arias E, Tejada-Vera B. Deaths: final data for 2018. Natl Vital Stat Rep. 2021;69:1–83.
Hayward KL, Johnson AL, Horsfall LU, Moser C, Valery PC, Powell EE. Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM. BMJ Open Gastroenterol. 2021;8:e000572.
Hagström H, Adams LA, Allen AM, Byrne CD, Chang Y, Grønbæk H, et al. Administrative Coding in electronic health care record-based research of NAFLD: An expert panel consensus statement. Hepatology. 2021;74:474–482.

Female

Humans

Male

Asian

Black or African American

Non-alcoholic Fatty Liver Disease

Racial Groups

United States

White

Adult

Middle Aged

Aged

Sex Factors

Age Factors

Journal Article

OpenLB
Open Library of Bioscience